What is irritable bowel syndrome and how is it treated?

Irritable bowel syndrome (IBS) is a common, chronic functional gastrointestinal disorder characterized by a cluster of symptoms—primarily recurrent abdominal pain directly associated with alterations in bowel habits—in the absence of detectable structural or biochemical abnormalities that would explain the discomfort. It is diagnosed clinically using established criteria, such as the Rome IV criteria, which emphasize the frequency and duration of pain linked to defecation and changes in stool form or frequency. The condition is subtyped based on the predominant stool pattern: IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), IBS with mixed bowel habits (IBS-M), or unclassified. Its pathophysiology is understood to be multifactorial, involving a complex interplay of gut-brain axis dysfunction, visceral hypersensitivity, altered gut motility, intestinal barrier function changes, immune activation, and shifts in the gut microbiota. Importantly, it is not a disease of inflammation in the classical sense, nor does it cause permanent damage to the digestive tract or increase cancer risk, but it significantly impairs quality of life and daily functioning.

Treatment is inherently patient-specific and multimodal, focusing on symptom management rather than cure, as no single therapy addresses the disorder's complex etiology. The cornerstone of initial management is a comprehensive therapeutic physician-patient relationship coupled with dietary and lifestyle modifications. A first-line dietary approach often involves a trial of a low-FODMAP diet, which restricts fermentable oligosaccharides, disaccharides, monosaccharides, and polyols that can draw water into the intestine and ferment to produce gas, thereby exacerbating bloating, pain, and altered motility. This elimination diet is typically conducted under dietitian supervision to ensure nutritional adequacy and proper reintroduction phases. Concurrently, stress management techniques, such as cognitive behavioral therapy, gut-directed hypnotherapy, or mindfulness, are recommended to modulate the gut-brain axis, given the well-established link between psychological stress and symptom exacerbation.

Pharmacological therapy is tailored to the predominant subtype and most bothersome symptoms. For IBS-C, osmotic laxatives like polyethylene glycol are first-line, while prescription agents include secretagogues like lubiprostone, linaclotide, or plecanatid, which increase intestinal fluid secretion and transit. For IBS-D, antidiarrheals like loperamide are used as needed, and gut-directed antispasmodics (e.g., hyoscine, dicyclomine) can alleviate pain and urgency. Second-line drugs for IBS-D include rifaximin, a non-systemic antibiotic with effects on the bacterial microbiome, or eluxadoline, which modulates opioid receptors in the gut. For all subtypes, low-dose tricyclic antidepressants are frequently employed for their neuromodulatory effects on visceral pain perception and central pain processing, independent of their psychiatric indications. Emerging treatments continue to explore the modulation of the gut microbiota through specific probiotics, though evidence supports strain-specific efficacy rather than a class effect.

The long-term management of IBS requires an ongoing, flexible strategy that may integrate these modalities sequentially or in combination. Patient education to understand the benign yet chronic nature of the condition is crucial to avoid unnecessary invasive procedures and to set realistic expectations for therapy, which aims for adequate symptom control rather than absolute resolution. Given the heterogeneity of the disorder, treatment success is often defined by a reduction in global symptom burden and improvement in daily life activities, achieved through a collaborative, stepwise process between the patient and clinician.